PTCL
These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.
These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and <span class="gene" id="24413734-3-91-95">IDH2</span> as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) <span class="disease" id="24413734-3-274-278">PTCL</span>, not otherwise specified (<span class="disease" id="24413734-3-305-309">PTCL</span>-NOS) samples.